DDInter118 DDInter927
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Aripiprazole {u} (Compound) resembles {v} (Compound) Nefazodone
Aripiprazole {u} (Compound) resembles {v} (Compound) Trazodone
Aripiprazole {u} (Compound) binds {v} (Gene) ADRA1B
Aripiprazole {u} (Compound) upregulates {v} (Gene) AARS
Aripiprazole {u} (Compound) palliates {v} (Disease) bipolar disorder
Aripiprazole {u} (Compound) downregulates {v} (Gene) PCNA
Aripiprazole {u} (Compound) causes {v} (Side Effect) Orthostatic hypotension
Aripiprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Aripiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Aripiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Aripiprazole (Compound) resembles Nefazodone (Compound)
Aripiprazole (Compound) resembles Trazodone (Compound)
Aripiprazole (Compound) binds ADRA1B (Gene)
Aripiprazole (Compound) upregulates AARS (Gene)
Aripiprazole (Compound) palliates bipolar disorder (Disease)
Aripiprazole (Compound) downregulates PCNA (Gene)
Aripiprazole (Compound) causes Orthostatic hypotension (Side Effect)
Aripiprazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Abarelix
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole